Ameripath Inc.
Palm Beach Gardens, FL Dermpath Diagnostics Part of Quest Diagnostics Incorporated
- UEI
- Q8CENGNQA374
- CAGE
- 7FWW4
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Quest Diagnostics Incorporated, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Secaucus, NJ
UC5SPMUJF8V3
-
- Ameripath Indianapolis PC · Indianapolis, IN S9BJUU9971G8
-
-
Parent
Secaucus, NJ
UC5SPMUJF8V3
- SAM.gov registration date
- Physical address
- 7108 Fairway Dr #335, Palm Beach Gardens, FL 33418, USA
- Website
- ameripath.com
- Founded
- 1996
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $102,531 |
| FY2025 | $161,094 |
| FY2024 | $107,950 |
| FY2023 | $96,979 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $102,531 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Todd, Robert M MD | Amarillo, TX | 621111 Offices of Physicians (except Mental Health Specialists) |
| Arup Laboratories Inc. | Salt Lake City, UT | 621511 Medical Laboratories |
| Utah Pathology Services, Inc. | Salt Lake City, UT | 621511 Medical Laboratories |
| Incyte Diagnostics | Spokane Valley, WA | 621111 Offices of Physicians (except Mental Health Specialists) |
| Stjoseph's Via Christy Medical Center | Wichita, KS | 621111 Offices of Physicians (except Mental Health Specialists) |
About the company
Ameripath Inc. Dermpath Diagnostics Division, a subsidiary of Quest Diagnostics Incorporated, provides anatomic pathology testing and dermatopathology laboratory services to the Department of Veterans Affairs as a prime contractor competing under full and open procedures with no set-aside designation. The division operates from Oklahoma City, Oklahoma and Tucson, Arizona, serving Veterans Integrated Service Networks (VISNs) across the southern regions. Ameripath is 100% prime in its federal footprint, with no subcontract work in the source data.
Ameripath's capability portfolio centers on specialized reference laboratory testing for pathology, grounded entirely in VA healthcare support. Services include dermatopathology consultations on prepared slides, renal biopsy specimen processing, immunofluorescence staining, specimen courier services, and direct-send reference testing for analyses not available in-house at VA medical centers. Representative work includes a $72,402 firm-fixed-price BPA call with VISN 22 awarded September 2024 for anatomic pathology testing with a completion date of September 2025, a $246,758 purchase order also with VISN 22 awarded May 2024 for dermpath testing services extending through April 2029, and a $218,193 definitive contract with VISN 22 awarded December 2023 for reference laboratory testing of renal biopsy specimens in Tucson, Arizona. The division also holds a $123,504 single-award blanket purchase agreement with VISN 19 established September 2024, extending through September 2029, which has generated three firm-fixed-price calls totaling $120,940 in awarded value.
Customer concentration is extreme and stable. All 22 awards serve three VA entities: VISN 22 accounts for 17 awards and $2.3 million in combined potential value (100% overlap between award-count and potential-value rankings), VISN 19 for 4 awards and $244 thousand, and Army Medical Command for 1 award and $140 thousand. VISN 22 in the Southern Arizona region dominates the footprint, with Ameripath holding multiple overlapping vehicles — an indefinite delivery contract (VA25816D0098) supporting 11 task orders and $975 thousand in combined potential value, and a blanket purchase agreement (36C25924A0043) generating 3 task orders and $121 thousand. Combined potential value across the entire footprint is $2.7 million, with $1.3 million obligated (49% realized).
Activity has been episodic rather than growth-trajectory: two awards in 2022, one in 2023, three in 2024, one in 2025, and one in 2026. Only one award faces completion within the next twenty-four months ($25 thousand in potential value), meaning recompete exposure is minimal. The division's federal work is concentrated entirely on NAICS 621511 (Medical Laboratories) and PSC reference laboratory testing, supporting VA pathology operations without competing in broader federal diagnostics or clinical laboratory markets outside the VA healthcare system.
Quick answers
Is Ameripath Inc. registered in SAM.gov?
Yes. Ameripath Inc.'s SAM.gov registration is active through December 9, 2026.
How much has Ameripath Inc. received in federal contracts?
Federal contracts obligated $161,094 to Ameripath Inc. in fiscal year 2025 and $468,553 in fiscal years 2023 through 2027.
How does Ameripath Inc. rank among federal contractors?
Ameripath Inc.'s parent company, Quest Diagnostics Incorporated, ranked #2 in NAICS 6215, #2 in PSC Q3 and #12 in NAICS 621 in FY2025.
What is Ameripath Inc.'s most recent federal award?
Ameripath Inc.'s most recent federal contract award is Anatomic pathology testing (36C25926N0502), from Veterans Integrated Service Network 19 (VHA), on September 30, 2026.
On GovTribe
See Ameripath Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors